Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma

Pancreatic Cancer Clinical Trial

Official title:

Phase I Study Combining Replication-Competent Adenovirus-Mediated Suicide Gene Therapy With Chemoradiotherapy for the Treatment of Non-Metastatic Pancreatic Adenocarcinoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00415454
• Other study ID #: Panc4242
• Secondary ID: P01CA097012
• Status: Terminated
• Phase: Phase 1
• First received: December 21, 2006
• Last updated: June 21, 2011
• Start date: November 2006

Study information

• Verified date: June 2011
• Source: Henry Ford Health System
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this phase I study is to determine the safety of combining replication-competent adenovirus-mediated suicide gene therapy with chemoradiotherapy in patients with non-metastatic pancreatic cancer.

Description:

The objectives of this study are:

To determine the toxicity and maximum tolerated dose (MTD) of the Ad5-yCD/mutTKSR39rep-ADP adenovirus in combination with 5-fluorocytosine (5-FC) and valganciclovir (vGCV) prodrug therapy and standard chemoradiation. Fifteen to 30 subjects (5 cohorts of 3 - 6 subjects each) with non-metastatic, unresectable pancreatic cancer will receive a single intratumoral injection of the Ad5-yCD/mutTKSR39rep-ADP adenovirus at one of five dose levels (1 x 10e10 vp, 3 x 10e10 vp, 1 x 10e11 vp, 3 x 10e11 vp, 1 x 10e12 vp) under endoscopic ultrasound (EUS)-guidance. Beginning three days later, subjects will receive 3 weeks (15 days) of 5-FC and vGCV prodrug therapy concomitant with a 6 week (30 day) course of capecitabine chemotherapy and 54 Gy conformal radiotherapy.

The primary endpoint is toxicity at 12 weeks. Secondary endpoints are: 1) tumor (radiological) response, 2) time to disease progression, 3) survival, 4) persistence of Ad5-yCD/mutTKSR39rep-ADP adenoviral DNA in blood, 5) infectious Ad5-yCD/mutTKSR39rep-ADP adenovirus in blood, and 6) HSV-1 TK gene expression in the pancreas.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Age > = 18 and < = 80.

• Non-metastatic, unresectable tumors

• No evidence of peritoneal and/or hematogenous metastasis.

• Histologically proven (biopsy or cytology) adenocarcinoma.

• No evidence of peritoneal and/or hematogenous metastasis.

• No prior chemotherapy, radiotherapy or biological therapy.

• ECOG performance status 0 - 2.

• Subjects must have adequate baseline organ function, as assessed by the following laboratory values, within 30 days before initiating the study therapy:

• Adequate renal function with serum creatinine <=1.5 mg/dL or creatinine clearance >=50 mL/min/m2.

• Absolute WBC > 4,000/µL.

• Hemoglobin > 9.0 g/dL.

• Platelet count > 100,000/µL.

• Bilirubin < 1.5 mg/dL; SGOT and SGPT < 2.5 times upper limit of normal (ULN).

• No history of malignancy within 5 years except for non-melanomatous skin cancer or carcinoma in situ of the cervix.

• Men and women with conceptive potential must agree to follow a medically acceptable method of birth control.

• Patients on oral warfarin anticoagulation therapy may be included in this study, but must have close monitoring of their coagulation parameters as altered parameters and/or bleeding have been reported in patients taking Xeloda® and such agents concomitantly.

• The subject must possess the ability to give informed consent and express a willingness to meet all of the expected requirements of the protocol for the duration of the study.

Exclusion Criteria:

• Pregnant and lactating women.

• Serious non-malignant disease (e.g., congestive heart failure or uncontrolled infections), which, in the opinion of the investigator would compromise study objectives.

• Major surgery within four weeks other than diagnostic procedures such as laparoscopy, endoscopic ultrasound and stenting or PEG/PEJ placement.

• Islet cell tumor, benign cyst, peri-ampullary carcinoma or any non-adenocarcinomas.

• Acute infection. Acute infection is defined by any viral, bacterial, or fungal infection that has required specific therapy within 72 hours of initiation of the study therapy (defined as Day 1).

• Active HIV disease.

• Previous history of liver disease including hepatitis.

• Positive serologic test for Hepatitis B or C at baseline.

• Immunosuppressive therapy including systemic corticosteroids. Use of inhaled and topical corticosteroids is permitted.

• Serious medical or psychiatric illness or concomitant medication, which, in the judgment of the investigator, might interfere with the subject's ability to respond to or tolerate the treatment or complete the trial.

• Impaired immunity or susceptibility to serious viral infections.

• Allergy to any product used on the protocol including ciprofloxacin.

• Clinical or laboratory evidence of pancreatitis

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Adenocarcinoma
• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Genetic:
• Ad5-yCD/mutTKSR39rep-ADP
Single injection on day 1 at one of five dose levels

Locations

Country	Name	City	State
United States	Henry Ford Health System	Detroit	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Henry Ford Health System

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Toxicity		12 weeks post adenovirus injection	Yes
Secondary	Tumor response		3 - 12 months	No
Secondary	Time to progression		3 - 12 months	No
Secondary	Survival		10 - 20 months	No
Secondary	Gene expression in pancreas		1 - 14 days	No